Michael Mann

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi Transcription factor decoys: a new model for disease intervention
    Michael J Mann
    Division of Cardiothoracic Surgery, University of California, San Francisco, California 94143, USA
    Ann N Y Acad Sci 1058:128-39. 2005
  2. ncbi Isolated pulmonary arteriovenous malformations requiring anatomic resection
    Michael J Mann
    Division of Cardiothoracic Surgery, University of California, San Francisco 94143, USA
    J Thorac Cardiovasc Surg 127:574-6. 2004
  3. ncbi Novel strategies for the prevention of bypass graft failure
    Michael J Mann
    Division of Cardiothoracic Surgery, University of California, San Francisco, California 94143, USA
    BioDrugs 18:1-8. 2004
  4. ncbi Molecular approaches for the treatment of atherosclerosis
    Michael J Mann
    Division of Cardiothoracic Surgery, University of California San Francisco, 505 Parnassus, San Francisco, CA, USA
    Cardiol Clin 20:633-43. 2002
  5. ncbi Transcription factor decoys for the prevention of vein bypass graft failure
    Michael J Mann
    Department of Surgery, Harvard Medical School, Brigham and Women's Hospital, Boston, Massachusetts, USA
    Am J Cardiovasc Drugs 3:79-85. 2003
  6. ncbi Reversal of direct thrombin inhibition after cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia
    Greg Stratmann
    Department of Anesthesia and Perioperative Care, University of California at San Francisco, Mailbox 0464, Room U 368 P, Moffitt Hospital, 513 Parnassus Avenue, San Francisco, CA 94143, USA
    Anesth Analg 98:1635-9, table of contents. 2004
  7. ncbi Use of bivalirudin, a direct thrombin inhibitor, and its reversal with modified ultrafiltration during heart transplantation in a patient with heparin-induced thrombocytopenia
    Michael J Mann
    Department of Surgery, University of California San Francisco, San Francisco, CA 94143, USA
    J Heart Lung Transplant 24:222-5. 2005
  8. ncbi Isolation and transplantation of autologous circulating endothelial cells into denuded vessels and prosthetic grafts: implications for cell-based vascular therapy
    Daniel P Griese
    Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 75 Francis St, Boston, Mass 02115, USA
    Circulation 108:2710-5. 2003
  9. ncbi Genetic interventions for vein bypass graft disease: a review
    Michael S Conte
    Department of Surgery, Brigham and Women's Hospital, Boston, MA 02115, USA
    J Vasc Surg 36:1040-52. 2002
  10. ncbi Endothelial healing in vein grafts: proliferative burst unimpaired by genetic therapy of neointimal disease
    Afshin Ehsan
    Department of Medicine, Harvard Medical School and Brigham and Women's Hospital, Boston, Mass 02115, USA
    Circulation 105:1686-92. 2002

Research Grants

  1. The role of S1P signaling in surgical cardiac remodeling
    Michael Mann; Fiscal Year: 2007
  2. ERK signaling and a hybrid surgical/molecular approach for chronic heart failure
    Michael Mann; Fiscal Year: 2009
  3. ERK signaling and a hybrid surgical/molecular approach for chronic heart failure
    Michael J Mann; Fiscal Year: 2010

Collaborators

Detail Information

Publications12

  1. ncbi Transcription factor decoys: a new model for disease intervention
    Michael J Mann
    Division of Cardiothoracic Surgery, University of California, San Francisco, California 94143, USA
    Ann N Y Acad Sci 1058:128-39. 2005
    ....
  2. ncbi Isolated pulmonary arteriovenous malformations requiring anatomic resection
    Michael J Mann
    Division of Cardiothoracic Surgery, University of California, San Francisco 94143, USA
    J Thorac Cardiovasc Surg 127:574-6. 2004
  3. ncbi Novel strategies for the prevention of bypass graft failure
    Michael J Mann
    Division of Cardiothoracic Surgery, University of California, San Francisco, California 94143, USA
    BioDrugs 18:1-8. 2004
    ..These include both gene transfer and gene blockade strategies...
  4. ncbi Molecular approaches for the treatment of atherosclerosis
    Michael J Mann
    Division of Cardiothoracic Surgery, University of California San Francisco, 505 Parnassus, San Francisco, CA, USA
    Cardiol Clin 20:633-43. 2002
    ..As the understanding of the genetic basis of vascular disease continues to grow and the tools for in vivo genetic manipulation continue to improve, vascular gene therapies might someday become a part of routine patient care...
  5. ncbi Transcription factor decoys for the prevention of vein bypass graft failure
    Michael J Mann
    Department of Surgery, Harvard Medical School, Brigham and Women's Hospital, Boston, Massachusetts, USA
    Am J Cardiovasc Drugs 3:79-85. 2003
    ..These studies herald the arrival of a new class of molecular agents into the armamentarium of cardiovascular therapies...
  6. ncbi Reversal of direct thrombin inhibition after cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia
    Greg Stratmann
    Department of Anesthesia and Perioperative Care, University of California at San Francisco, Mailbox 0464, Room U 368 P, Moffitt Hospital, 513 Parnassus Avenue, San Francisco, CA 94143, USA
    Anesth Analg 98:1635-9, table of contents. 2004
    ..IMPLICATIONS: A combination of modified ultrafiltration, hemodialysis, and the administration of recombinant factor VIIa, fresh frozen plasma, and cryoprecipitate may reverse the anticoagulant effect of bivalirudin...
  7. ncbi Use of bivalirudin, a direct thrombin inhibitor, and its reversal with modified ultrafiltration during heart transplantation in a patient with heparin-induced thrombocytopenia
    Michael J Mann
    Department of Surgery, University of California San Francisco, San Francisco, CA 94143, USA
    J Heart Lung Transplant 24:222-5. 2005
    ..Herein we describe the dosing and intraoperative management of bivalrudin anti-coagulation in a patient undergoing urgent cardiac transplantation in the context of recently diagnosed HIT...
  8. ncbi Isolation and transplantation of autologous circulating endothelial cells into denuded vessels and prosthetic grafts: implications for cell-based vascular therapy
    Daniel P Griese
    Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 75 Francis St, Boston, Mass 02115, USA
    Circulation 108:2710-5. 2003
    ..These findings may have implications for novel and practical cell-based therapies for vascular disease...
  9. ncbi Genetic interventions for vein bypass graft disease: a review
    Michael S Conte
    Department of Surgery, Brigham and Women's Hospital, Boston, MA 02115, USA
    J Vasc Surg 36:1040-52. 2002
    ..This review describes the basic and translational science of genetic interventions for vein graft disease and the current state of application in the clinic...
  10. ncbi Endothelial healing in vein grafts: proliferative burst unimpaired by genetic therapy of neointimal disease
    Afshin Ehsan
    Department of Medicine, Harvard Medical School and Brigham and Women's Hospital, Boston, Mass 02115, USA
    Circulation 105:1686-92. 2002
    ..Additionally, there is a selective effect of E2F decoy gene therapy on target smooth muscle cells with sparing of this endothelial healing...
  11. ncbi Cell cycle-dependent regulation of smooth muscle cell activation
    Ruediger C Braun-Dullaeus
    Cardiothoracic Surgery, University of California, San Francisco Medical School, San Francisco, Calif, USA
    Arterioscler Thromb Vasc Biol 24:845-50. 2004
    ....
  12. ncbi Gene therapy strategy for long-term myocardial protection using adeno-associated virus-mediated delivery of heme oxygenase gene
    Luis G Melo
    Department of Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts, USA
    Circulation 105:602-7. 2002
    ....

Research Grants8

  1. The role of S1P signaling in surgical cardiac remodeling
    Michael Mann; Fiscal Year: 2007
    ..Finally, pharmacologic stimulation of SphK1 and gene transfer of S1 P! And of SphK1 will test the feasibility of an intra-operative, molecular enhancement of surgical TCR. (End of Abstract) ..
  2. ERK signaling and a hybrid surgical/molecular approach for chronic heart failure
    Michael Mann; Fiscal Year: 2009
    ....
  3. ERK signaling and a hybrid surgical/molecular approach for chronic heart failure
    Michael J Mann; Fiscal Year: 2010
    ....